Semaglutide cut liver cancer burden but not fibrosis in MASLD mice

The wire

1. 01In a C57BL/6J diet-and-carbon-tetrachloride MASLD model, semaglutide monotherapy lowered body weight and hepatocellular carcinoma burden (p<0.0001), while picrosirius red fibrosis did not differ across groups (p=0.1725).
2. 02The authors frame the result as evidence that metabolic correction alone may not reverse self-sustaining fibrogenesis in advanced disease.
3. 03This is a mouse model with no human data; the authors describe stage-dependent constraints on combination therapy rather than a negative verdict on either agent.

From the source

Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model

PloS one · 2026 · Goodman AZ, Stauffer WT, Gallay PA et al.